Ranbaxy Farmaceutica Ltda :

Ranbaxy Farmaceutica Ltda. is a Brazilian pharmaceutical company specializing in the wholesale distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on November 4, 1993, the company is headquartered in Rio de Janeiro, Brazil. It operates under the legal structure of a Sociedade Empresária Limitada (Limited Liability Company), with a capital social of R$ 17,366,914.00.

The company's primary activity is the wholesale distribution of human-use pharmaceuticals, as classified under the CNAE code 46.44-3/01. Ranbaxy Farmaceutica Ltda. has expanded its operations with additional facilities in Barueri, São Paulo, and Goiânia, Goiás, indicating a strategic approach to enhance its distribution capabilities across Brazil. (econodata.com.br)

Ranbaxy Farmaceutica Ltda. has established a robust distribution network with multiple facilities across Brazil. The main office is located at Rua Francisco de Souza Melo, 252, Cordovil, Rio de Janeiro, RJ, 21.010-410. Additional facilities include a branch in Barueri, São Paulo, situated at Alameda Tocantins, 125, Alphaville Industrial, and another in Goiânia, Goiás, at Avenida Doutor Napoleão R. Laureano, 2821, Fazenda Planície. (econodata.com.br)

These strategically located warehouses enable Ranbaxy Farmaceutica Ltda. to effectively manage logistics and ensure timely delivery of pharmaceutical products throughout Brazil. The company's distribution network is designed to support its extensive import operations, facilitating the efficient movement of goods from suppliers to end-users across the country.

Ranbaxy Farmaceutica Ltda. plays a significant role in Brazil's pharmaceutical supply chain as a primary wholesaler. The company imports a diverse range of finished pharmaceutical formulations from India, including advanced diabetes medications, vitamins, and nutritional supplements. By sourcing these products, Ranbaxy Farmaceutica Ltda. contributes to the availability of essential medications in the Brazilian market, catering to various therapeutic needs.

The company's operations are characterized by a high degree of supplier concentration, primarily importing from a single supplier, SUN PHARMACEUTICAL INDUSTRIES LIMITED. This sourcing strategy underscores Ranbaxy Farmaceutica Ltda.'s reliance on established partnerships to meet the pharmaceutical demands of the Brazilian market.

Ranbaxy Farmaceutica Ltda.'s sourcing strategy exhibits a high degree of concentration, with 100% of its pharmaceutical imports originating from SUN PHARMACEUTICAL INDUSTRIES LIMITED. This exclusive partnership indicates a strategic choice to maintain a streamlined supply chain and potentially negotiate favorable terms.

However, such dependency on a single supplier introduces risks related to supply chain disruptions, price fluctuations, and potential regulatory changes affecting the supplier. The stability of this relationship is crucial for Ranbaxy Farmaceutica Ltda.'s operations, and any challenges faced by SUN PHARMACEUTICAL INDUSTRIES LIMITED could directly impact the company's ability to meet market demands.

The resilience of Ranbaxy Farmaceutica Ltda.'s supply chain is closely tied to the stability and reliability of SUN PHARMACEUTICAL INDUSTRIES LIMITED. Given the exclusive nature of this partnership, the company may face challenges in diversifying its supplier base. The absence of backup suppliers could pose risks in the event of supply chain disruptions, such as production delays or logistical issues.

Additionally, the company's focus on a limited range of formulations, with 787 unique formulations imported, suggests a specialized product portfolio. While this specialization can enhance operational efficiency, it may also limit flexibility in adapting to changing market demands or regulatory requirements.

Ranbaxy Farmaceutica Ltda.'s concentrated sourcing strategy positions it to leverage strong relationships with its supplier, potentially securing favorable pricing and consistent product quality. This approach can enhance the company's competitive edge in the Brazilian pharmaceutical market.

For Indian exporters, the exclusive partnership with SUN PHARMACEUTICAL INDUSTRIES LIMITED presents an opportunity to explore alternative supply channels to Ranbaxy Farmaceutica Ltda. Diversifying the supplier base could mitigate risks associated with supply chain disruptions and open avenues for new business relationships.

In Brazil, the regulation of pharmaceutical products is overseen by the Agência Nacional de Vigilância Sanitária (ANVISA), the National Health Surveillance Agency. ANVISA is responsible for ensuring the safety, efficacy, and quality of health-related products, including pharmaceuticals. (gov.br)

Key legislation governing pharmaceutical imports includes Law No. 9,782/1999, which established ANVISA, and Law No. 6,360/1976, which regulates the manufacture and marketing of pharmaceutical products. These laws outline the requirements for product registration, importation, and distribution within Brazil.

Import licensing in Brazil requires that pharmaceutical products be registered with ANVISA before they can be marketed. This process involves submitting detailed documentation, including evidence of Good Manufacturing Practice (GMP) compliance. ANVISA recognizes GMP certifications from various international standards, such as EU GMP, WHO GMP, and PIC/S, facilitating the importation of products manufactured under these guidelines. (gov.br)

Wholesalers like Ranbaxy Farmaceutica Ltda. must obtain authorization from ANVISA to distribute pharmaceutical products. This authorization ensures that the company adheres to regulatory standards concerning storage, handling, and distribution, maintaining the integrity and safety of the pharmaceutical supply chain.

Pharmaceutical products imported into Brazil are subject to batch testing and stability requirements to ensure their safety and efficacy. ANVISA mandates that imported drugs undergo quality control procedures, including testing for purity, potency, and stability, to meet Brazilian standards. (gov.br)

Labeling requirements stipulate that product information be provided in Portuguese, including dosage instructions, indications, contraindications, and storage conditions. Serialization mandates are also in place to enhance traceability and prevent counterfeit products from entering the market.

Between 2024 and 2026, Brazil implemented several regulatory changes affecting pharmaceutical imports. ANVISA introduced stricter guidelines for product registration, emphasizing the need for comprehensive clinical data and GMP compliance. Additionally, new labeling requirements were enforced, mandating the inclusion of QR codes for product verification. These changes aim to enhance product traceability and consumer safety.

Ranbaxy Farmaceutica Ltda.'s focus on advanced diabetes medications, vitamins, and nutritional supplements aligns with the growing demand for chronic disease management and preventive healthcare in Brazil. The prevalence of diabetes and other lifestyle-related conditions has increased, driving the need for effective therapeutic options.

The company's import strategy reflects an understanding of market needs, positioning itself to provide essential medications that address prevalent health issues. By sourcing these products from India, Ranbaxy Farmaceutica Ltda. leverages cost-effective manufacturing while meeting the therapeutic demands of the Brazilian population.

Ranbaxy Farmaceutica Ltda. employs a sourcing strategy that emphasizes the importation of generic drugs, focusing on finished pharmaceutical formulations. This approach allows the company to offer affordable therapeutic options to the Brazilian market. The preference for formulations that address chronic conditions, such as diabetes, indicates a strategic alignment with prevalent health concerns.

India's established pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a suitable partner for Ranbaxy Farmaceutica Ltda.'s procurement needs. The company's sourcing profile reflects a commitment to quality, affordability, and responsiveness to market demands.

Based on its product mix, Ranbaxy Farmaceutica Ltda. serves the Brazilian pharmaceutical market through wholesale distribution channels. By importing and distributing a range of pharmaceutical products, the company plays a pivotal role in ensuring the availability of essential medications across the country.

The focus on chronic disease management and preventive healthcare positions Ranbaxy Farmaceutica Ltda. to cater to both retail pharmacies and hospital suppliers, addressing the needs of a diverse patient population.

There is a realistic opportunity for new Indian suppliers to engage with Ranbaxy Farmaceutica Ltda. by offering complementary products that align with the company's existing portfolio. Introducing innovative formulations or addressing unmet therapeutic needs could enhance the company's product offerings and market competitiveness.

Identifying gaps in Ranbaxy Farmaceutica Ltda.'s current sourcing, such as the need for additional suppliers to mitigate risks associated with single-source dependency, presents an opportunity for Indian exporters to establish partnerships and diversify the company's